tiprankstipranks
Trending News
More News >
Trajan Group Holdings Ltd (AU:TRJ)
ASX:TRJ
Australian Market
Advertisement

Trajan Group Holdings Ltd (TRJ) AI Stock Analysis

Compare
8 Followers

Top Page

AU:TRJ

Trajan Group Holdings Ltd

(Sydney:TRJ)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
AU$0.50
▼(-30.56% Downside)
Trajan Group Holdings Ltd faces significant challenges, primarily due to its negative net income and weak cash flow management, which impact its financial performance. The technical indicators suggest a bearish trend, and the negative P/E ratio highlights valuation concerns. These factors collectively result in a lower overall stock score.

Trajan Group Holdings Ltd (TRJ) vs. iShares MSCI Australia ETF (EWA)

Trajan Group Holdings Ltd Business Overview & Revenue Model

Company DescriptionTrajan Group Holdings Limited develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company operates through two segments, Analytical Products and Life Science Solutions. It offers analytical products, including syringes, GC consumables, septas, caps, liners, gas filters, and tubing products; pathology solutions; and sampling products, as well as automation systems for the analysis of biological, food, and environmental samples. The company also provides nutrition testing solutions for pathology laboratories, research and clinical trials, personalized nutrition, corporate wellness, and health insurance. In addition, it offers automation workflow solutions, micro sampling devices, and data analysis services. Trajan Group Holdings Limited was incorporated in 2011 and is headquartered in Ringwood, Australia.
How the Company Makes MoneyTrajan Group Holdings generates revenue through multiple key streams, primarily from the sale of its innovative laboratory and analytical products. The company profits by providing specialized consumables and equipment to laboratories, research institutions, and healthcare providers. Additionally, Trajan engages in partnerships and collaborations with other organizations in the healthcare sector, enhancing its market reach and technological capabilities. The company also focuses on recurring revenue through consumables, which are essential for ongoing laboratory operations, thereby establishing a stable income base. Furthermore, Trajan may benefit from strategic acquisitions that expand its product offerings and market presence.

Trajan Group Holdings Ltd Financial Statement Overview

Summary
Trajan Group Holdings Ltd is experiencing moderate revenue growth but is facing profitability challenges with negative net income. The balance sheet shows a stable equity position but is impacted by the negative return on equity. Cash flow management needs improvement, particularly in generating free cash flow. The company should focus on enhancing operational efficiency and profitability to strengthen its financial position.
Income Statement
55
Neutral
Trajan Group Holdings Ltd has shown a modest revenue growth rate of 4.29% in the most recent year, indicating a positive trend. However, the company is currently experiencing negative net income, resulting in a negative net profit margin. The gross profit margin is relatively healthy, but the EBIT and EBITDA margins are low, suggesting challenges in operational efficiency and cost management.
Balance Sheet
60
Neutral
The company's debt-to-equity ratio is moderate, indicating a balanced approach to leveraging. However, the return on equity is negative due to the net loss, which is a concern. The equity ratio is stable, showing a solid foundation of equity relative to total assets.
Cash Flow
50
Neutral
Free cash flow has decreased by 20.04%, which is a negative indicator. The operating cash flow is positive and covers net income, but the free cash flow to net income ratio is not favorable due to the net loss. The company needs to improve its cash flow generation to support operations and growth.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue159.62M166.46M155.02M162.15M107.57M76.57M
Gross Profit60.24M63.47M59.75M22.93M42.63M28.48M
EBITDA10.95M8.14M-20.36M14.86M5.14M3.46M
Net Income-28.48M-4.46M-25.33M1.89M1.70M1.88M
Balance Sheet
Total Assets199.03M195.63M188.00M229.04M206.78M99.38M
Cash, Cash Equivalents and Short-Term Investments10.44M11.85M11.24M11.04M13.16M51.72M
Total Debt55.94M55.49M56.16M61.30M66.18M17.02M
Total Liabilities93.36M90.01M85.15M99.51M90.27M33.30M
Stockholders Equity105.67M105.62M102.85M129.53M116.51M66.08M
Cash Flow
Free Cash Flow8.43M6.74M6.43M998.00K-1.28M8.34M
Operating Cash Flow11.95M10.83M9.47M9.55M2.13M9.45M
Investing Cash Flow-3.52M-4.09M-3.04M-8.55M-116.38M402.00K
Financing Cash Flow-9.99M-5.64M-6.40M-3.36M74.69M36.81M

Trajan Group Holdings Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.72
Price Trends
50DMA
0.79
Negative
100DMA
0.80
Negative
200DMA
0.82
Negative
Market Momentum
MACD
-0.02
Positive
RSI
35.71
Neutral
STOCH
-0.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRJ, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.79, and below the 200-day MA of 0.82, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 35.71 is Neutral, neither overbought nor oversold. The STOCH value of -0.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRJ.

Trajan Group Holdings Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
AU$164.89M26.9912.35%39.98%-30.04%
64
Neutral
AU$105.20M15.2927.24%1.60%0.65%-9.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
AU$119.74M-26.79-4.28%7.38%82.39%
41
Neutral
AU$70.02M-5.38-31.98%34.20%-23.90%
40
Underperform
AU$84.39M-11.89
40
Underperform
AU$106.68M-13.09-47.98%700.00%26.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:TRJ
Trajan Group Holdings Ltd
0.72
-0.46
-38.98%
AU:AHC
Austco Healthcare Limited
0.44
0.19
74.00%
AU:CYC
Cyclopharm Limited
0.63
-0.74
-54.01%
AU:SHG
Singular Health Group Ltd
0.27
0.19
237.50%
AU:EZZ
EZZ Life Science Holdings Ltd.
2.42
-0.48
-16.55%
AU:ALA
Arovella Therapeutics Limited
0.09
-0.10
-53.68%

Trajan Group Holdings Ltd Corporate Events

Trajan Group Holdings Announces Director Resignation
Oct 28, 2025

Trajan Group Holdings Ltd has announced the resignation of Sara Watts from its board of directors, effective October 28, 2025. This change in leadership may influence the company’s strategic direction and stakeholder relations, as Watts held significant shares both personally and through JESET Pty Ltd, indicating a notable shift in the company’s governance structure.

The most recent analyst rating on (AU:TRJ) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Successfully Concludes 2025 AGM with All Resolutions Passed
Oct 28, 2025

Trajan Group Holdings Limited held its 2025 Annual General Meeting, where all resolutions presented to shareholders were carried with significant majorities. The resolutions included the adoption of the remuneration report and the granting of options to directors, reflecting strong shareholder support for the company’s strategic direction and governance. This outcome reinforces Trajan’s stable position in the analytical science industry and indicates continued confidence from its stakeholders.

The most recent analyst rating on (AU:TRJ) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Reports Strong Growth and Sustainability Advances
Oct 28, 2025

Trajan Group Holdings Ltd reported a strong financial performance with a revenue of $166.5 million, reflecting a growth of over 7% despite economic and political uncertainties. The company’s strategic focus on quality and regional manufacturing allowed it to quickly adapt to challenges, launching new product lines in Malaysia within eight weeks. Trajan also emphasized its commitment to sustainability, achieving a ‘good’ EcoVadis sustainability score and transitioning to renewable energy in key regions. The company aims to build long-term value through commercial success and transparent shareholder communication.

The most recent analyst rating on (AU:TRJ) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Issues Unquoted Equity Securities
Oct 6, 2025

Trajan Group Holdings Ltd has announced the issuance of 667,500 unquoted equity securities under an employee incentive scheme, which are subject to transfer restrictions and will not be quoted on the ASX until these restrictions are lifted. This move is part of the company’s strategy to incentivize employees, potentially impacting its operational dynamics by aligning employee interests with company performance, although it does not have immediate implications for external stakeholders.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Announces 2025 Annual General Meeting
Sep 25, 2025

Trajan Group Holdings Limited has announced its Annual General Meeting scheduled for October 28, 2025. This meeting will be held online and is a significant event for shareholders, as it will include the presentation of key documents such as the Notice of Annual General Meeting and a Sample Proxy Form. This announcement underscores Trajan’s commitment to maintaining transparency and engagement with its stakeholders, reflecting its strategic focus on expanding its influence in the analytical and life sciences industry.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Director Increases Stake Through Option Conversion
Sep 14, 2025

Trajan Group Holdings Ltd announced a change in the interest of its director, Sara Watts, who has converted 82,493 unlisted options into ordinary shares under the company’s Long Term Incentive Plan. This change increases her direct holding to 141,257 ordinary shares, reflecting a strategic move to align with the company’s growth objectives and potentially enhance shareholder value.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Updates Director’s Interest
Sep 14, 2025

Trajan Group Holdings Ltd has announced a change in the director’s interest notice, specifically concerning John Eales. The update details the acquisition of 79,533 ordinary shares and the disposal of an equal number of unlisted options. This change reflects an increase in direct shareholding for John Eales, which may indicate a strategic move to consolidate his position within the company.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Issues New Shares to Bolster Growth
Sep 12, 2025

Trajan Group Holdings Ltd has announced the issuance of 162,026 ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The company has complied with relevant provisions of the Corporations Act and confirmed there is no excluded information required to be disclosed. This issuance is part of Trajan’s ongoing efforts to support its growth and operations in the analytical and life sciences industry.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Ltd Announces Quotation of New Securities
Sep 12, 2025

Trajan Group Holdings Ltd has announced the quotation of 162,026 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code TRJ. This move is part of the company’s strategy to enhance its market presence and provide liquidity to its shareholders, potentially impacting its operational dynamics and stakeholder engagement.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Announces Board Changes Ahead of 2025 AGM
Sep 8, 2025

Trajan Group Holdings Limited announced that Sara Watts, Non-executive Director and Chair of the Audit and Risk Committee, will retire from the Board and not seek re-election at the 2025 Annual General Meeting. Her departure marks the end of her tenure since joining the Board in March 2021, just before the company’s IPO. Tiffiny Lewin will take over as Chair of the Audit and Risk Committee. This change in leadership may impact the company’s governance and strategic direction as it continues to focus on using science and medical technology to improve human wellbeing.

The most recent analyst rating on (AU:TRJ) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Ltd Releases Corporate Governance Statement
Aug 27, 2025

Trajan Group Holdings Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms that the company has adhered to the ASX Corporate Governance Council’s principles and recommendations, ensuring transparency and accountability in its management and oversight practices.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Ltd Advances in High Precision and Disruptive Technologies
Aug 27, 2025

Trajan Group Holdings Ltd is a leader in high precision products and services, offering a range of components, consumables, and capital equipment across various sectors. The company’s latest announcement highlights its commitment to innovation through disruptive technologies, aiming to enhance its market position and provide advanced solutions for stakeholders in biological, food, and environmental industries.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings to Release FY25 Results with Investor Engagement
Aug 7, 2025

Trajan Group Holdings Limited announced it will release its Full Year Results for the Financial Year ending June 30, 2025, on August 28, 2025. A live webcast and Q&A session will be hosted by the company’s CEO and CFO, allowing investors to engage and submit questions. This announcement is part of Trajan’s ongoing efforts to maintain transparency and engage with its stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 06, 2025